Portland Myeloma Roundtable image

Portland Myeloma Roundtable

Nov 07, 2026
08:00AM - 02:30PM PST In the city timezone
Marriott Downtown Waterfront
1401 SW Naito Pkwy, Portland, OR 97201, USA
$ 25
Overview

Join us for the Portland Myeloma Roundtable on November 7th to hear directly from leading myeloma experts about the latest in treatment and research. Designed specifically for patients and caregivers, the event includes patient-friendly presentations, breakout sessions for newly diagnosed and relapsed/refractory patients, and a dedicated faculty Q&A with plenty of time to ask questions.

Meeting Details

Registration & breakfast 8:00 am

Program: 9:00 am - 2:30 pm

Location: Marriott Downtown Waterfront

Included: Breakfast, lunch, refreshments, and parking

Nearest airport: Portland International Airport (PDX)

Unable to attend in person? Register to receive access to the event recording.

This event will not be livestreamed. The recording will be available approximately one week after the event, and registered individuals will receive an email when it is ready.

Make it a weekend

If you are traveling to the meeting and would like to make a weekend of it while you are in Portland, here are some suggestions:

Questions?

For registration questions, contact us at  +1 800 709 1113 or email us at support@healthtree.org

To ensure we can continue providing you with excellent venues, quality meals, and a valuable experience at our Roundtable meetings, we're introducing a modest registration fee. If the fee is a financial burden, please contact us for a promotional code to waive the cost.

User uploaded media

Agenda
8:00 AM
Breakfast & Registration
9:00 AM
Welcome and Introduction
Jenny Ahlstrom
9:15 AM
Newly Diagnosed Myeloma: Building Your Treatment Foundation While Protecting Long-Term Health and Quality of Life
Rebecca Silbermann, MD, MMS

  • Understanding today’s frontline treatment options, including quadruplet therapy, and how MRD can help guide care.

  • Protecting bone health, managing side effects, and maintaining quality of life throughout treatment.

9:45 AM
High-Risk SMM and Myeloma: Assessing Risk and Making Treatment Decisions
Eva Medvedova, MD

  • Understanding how doctors identify high-risk disease, including risk assessments, MRD, and other tools used to evaluate SMM and myeloma.

  • How treatment strategies are evolving for patients with high-risk SMM and high-risk myeloma.

10:15 AM
Break
10:30 AM
New Approaches in Relapsed/Refractory Myeloma: Bispecifics, ADCs, CELMoDs & Beyond
Richa Thakur, MD

  • Understanding how bispecific antibodies, antibody-drug conjugates (ADCs), and CELMoDs are expanding treatment options for relapsed/refractory myeloma.

  • How these newer therapies may fit into treatment decisions and sequencing as options continue to evolve.

11:00 AM
HealthTree Cure Hub
Jenny Ahlstrom
11:15 AM
Breakout Sessions

Newly Diagnosed - Myeloma Care as You Age: Balancing Treatment, Strength, and Quality of Life, Jacqueline Trussell, AGACNP-BC, FNP-BC

OR

Relapsed Refractory - Can We Talk About “Cure” in Myeloma? What MRD Can—and Can’t—Tell Us, Rebecca Silbermann, MD

12:00 PM
Lunch
1:00 PM
CAR T in Myeloma: Understanding the Journey from Collection to Recovery
Andy Chen, MD, PhD

  • How CAR T works, who may be eligible, and when it may be considered.

  • What to expect from cell collection through treatment, recovery, and follow-up.

  •  Where stem cell transplant fits in the age of CAR T and what patients should consider when discussing these options with their care team.

1:30 PM
Round Table Audience Q&A with Faculty

  • Rebecca Silbermann, MD

  • Eva Medvedova, MD

  • Richa Thakur, MD,

  • Andy Chen, MD, PhD

  • Jacqueline Trussell, AGACNP-BC, FNP-BC.

2:15 PM
Help with HealthTree
Speakers & Moderators
Healthtree contact Jenny Ahlstrom

Jenny Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Healthtree contact Rebecca Silbermann, MD, MMS

Rebecca Silbermann, MD, MMS

“A cancer diagnosis is often complicated, frightening, and confusing. I try to help my patients understand their disease and their treatment choices so that we can work towards the best possible outcomes together.” Dr. Silbermann is a physician-scientist with expertise in multiple myeloma and other plasma cell disorders. She has a particular interest in myeloma bone disease and a research program focused on maintaining and improving bone health in myeloma patients. Dr. Silbermann has two children and spends her free time exploring the Portland area with her family.
Healthtree contact Eva Medvedova, MD

Eva Medvedova, MD

Eva Medvedova, MD, is an Assistant Professor of Medicine at Oregon Health & Science University (OHSU). She specializes in the care of adults with plasma cell disorders, including multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance (MGUS). She completed her internal medicine residency and hematology/oncology fellowship at the University of Massachusetts Medical School and is board certified in internal medicine, hematology, and medical oncology.
Healthtree contact Richa Thakur, MD

Richa Thakur, MD

is a hematology-oncology physician at Fred Hutch Cancer Center and an Assistant Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine. Her clinical practice focuses on plasma cell disorders, including multiple myeloma and amyloidosis, as well as quality of life. She has specialized training in both hematology/medical oncology and hospice and palliative care, bringing a patient-centered approach to treatment and symptom management.
Healthtree contact Andy Chen, MD, PhD

Andy Chen, MD, PhD

is an Associate Professor of Medicine in the Division of Hematology/Medical Oncology at Oregon Health & Science University (OHSU). He specializes in lymphoma and related hematologic malignancies, with a clinical focus that includes bone marrow transplantation. His research explores new treatments for lymphoma, with a particular interest in CAR-T cell therapy. Dr. Chen completed his residency and fellowship training at Stanford University and is board certified in hematology and medical oncology.
Healthtree contact Jacqueline Trussell, AGACNP-BC, FNP-BC

Jacqueline Trussell, AGACNP-BC, FNP-BC

is a Senior Outpatient Advanced Practice Provider and Instructor in the Autologous Stem Cell Transplant and Cellular Therapy Program at the OHSU Knight Cancer Institute. She provides care for patients before and after autologous stem cell transplant and cellular therapy, including long-term follow-up. Her clinical expertise includes the recognition and management of transplant- and cell therapy-related toxicities, including cytokine release syndrome (CRS), ICANS, and prolonged cytopenias. She also serves as a sub-investigator on cellular therapy clinical trials and has practiced as an inpatient and outpatient APP at OHSU since 2013.